Incretin and adipose-axis peptides — the most actively studied class in modern peptide research.
Metabolic peptides are the signaling molecules the body already uses to coordinate glucose handling, satiety, and energy expenditure. The current research wave centers on incretin biology — the gut-derived hormones that tune insulin secretion to nutrient intake — and on engineered analogs that extend those short-lived native signals into durable pharmacology. This page is a research reference to the mechanisms involved and the compounds catalogued here; it is not medical or dosing guidance.
Native incretins such as GLP-1 and GIP are released from the gut in response to nutrients and act on pancreatic, gastric, and central targets — but they are degraded within minutes by DPP-4. The defining engineering problem for this class has been resistance to that degradation: amino-acid substitutions, fatty-acid acylation, and albumin-binding moieties all extend half-life from minutes to days, converting a transient meal signal into a once-weekly pharmacological one.
Single-receptor GLP-1 agonism drives glucose-dependent insulin secretion, slowed gastric emptying, and central appetite suppression. Dual GIP/GLP-1 co-agonism layers a complementary insulinotropic and adipose-tissue signal on top of that. Triple agonism adds glucagon-receptor activity, which is associated in research with increased energy expenditure and hepatic lipid handling — the rationale behind the steepest body-composition endpoints reported in recent trials.
A parallel branch of the class works outside the incretin system entirely. Amylin analogs recruit calcitonin and amylin receptors for a distinct satiety signal studied in combination with GLP-1 agonists. Other catalogued compounds act on adipose tissue or cofactor metabolism directly rather than through gut-hormone receptors, which is why this category spans more than the GLP-1 headline names.
Long-acting GLP-1 receptor agonist for glycemic control and weight management.
View profileDual GIP / GLP-1 receptor agonist with industry-leading weight-loss endpoints.
View profileInvestigational triple agonist (GIP / GLP-1 / glucagon) in late-stage trials.
View profileLong-acting amylin analog studied alongside semaglutide as CagriSema.
View profileThe archetypal protein biologic — a 51-amino-acid two-chain hormone, disulfide-linked, and the first recombinant DNA drug ever marketed.
View profileInsulin’s counter-hormone — a 29-amino-acid peptide that raises blood glucose, the emergency rescue for severe lows, and the "G" in the new triple agonists.
View profileGHRH analog FDA-approved for HIV-associated lipodystrophy.
View profileThe body’s brake on muscle growth — a TGF-β-family growth factor whose inhibition is the leading strategy to preserve muscle, including during GLP-1 weight loss.
View profileA natural myostatin and activin antagonist — by neutralizing the muscle brake it is one of the most potent pro-muscle factors studied, and a doping and gene-therapy flashpoint.
View profileA monoclonal antibody that selectively blocks pro/latent myostatin — the muscle brake — studied to preserve lean mass during GLP-1 weight loss.
View profileAn anti-myostatin antibody (Regeneron) now studied in obesity combinations to cut lean-mass loss and deepen fat loss alongside semaglutide.
View profileA "sweeping" anti-myostatin antibody (Roche/Chugai) that not only blocks but actively clears myostatin — a cautionary case after its rare-disease trials failed.
View profileAn anti-activin-A antibody (Regeneron) — closest to approval of the axis (FOP), and a partner in obesity muscle-preservation combinations.
View profileAn antibody that blocks the activin type II receptor itself — shutting off myostatin AND activin signaling at once; famous for adding muscle while cutting fat.
View profileMitochondrially-encoded peptide with reported insulin-sensitizing activity.
View profileC-terminal hGH fragment (177–191) historically investigated for lipolysis.
View profileSmall-molecule NNMT inhibitor (often catalogued alongside peptides).
View profileIn this catalog, a metabolic peptide is a peptide or peptide-like compound whose primary studied activity is on glucose handling, satiety, or energy expenditure — most commonly through the incretin receptors (GLP-1, GIP, glucagon) or the amylin system. Entries are reference profiles, not products or treatment recommendations.
A GLP-1 agonist activates a single incretin receptor. Dual agonists (GIP/GLP-1) co-activate two complementary pathways; triple agonists add glucagon-receptor activity associated with increased energy expenditure in research. Each added axis is, broadly, associated with larger body-composition effects in published trials, alongside a distinct research and tolerability profile.
Native incretins are cleared within minutes by the enzyme DPP-4. Substitutions, fatty-acid acylation, and albumin-binding linkers make analogs resistant to that clearance, extending exposure from minutes to days and enabling once-weekly research dosing schedules.
No. AmericanPeptide.com is a computational research and reference platform, not a medical device or clinical decision-support system. Nothing here is medical advice, a dosing protocol, or an offer to sell. Independent expert and regulatory review is required before any experimental use.